# US 2010/0136029 A1 · Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136029 A1
- Document ID: US20100136029A1
- Status: Published application
- Kind: A1
- Application number: 12/520,354
- Filed: 2007-11-09
- Published: 2010-06-03
- Earliest claimed: 2006-12-20
- Assignees: Universitätsklinikum Hamburg-Eppendorf; Alphaptose GmbH
- Inventors: Axel Rolf Zander; Francis Ayuk Ayuketang; Wolfgang Richter; Lutz Weber
- Web page: https://patentgrep.com/patent/US20100136029A1

## CPC

- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 39/39533: {against materials from animals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07F 9/091: {with hydroxyalkyl compounds with further substituents on alkyl}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

Use of a tri-substituted glycerol compound according to formula (I)
or an enantiomer or diastereomer or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient for the manufacture of a medicament for the treatment of hematological malignancies, wherein
X is selected from the group consisting of phosphate and sulfate;
R1 is selected from the group consisting of C16-C20 alkyl;
R2 is selected from the group consisting of C1-C3 alkyl and C1-C3 hydroxyalkyl;
R3 is selected from the group consisting of hydrogen and C1-C3 alkyl;
R4 is selected from the group consisting of C1-C3 alkyl and C3-C6 cycloalkyl; and
R5 is selected from the group consisting of hydrogen and methyl.

### Claim 31 (depends on 30)

The use according to claim 30, wherein X is phosphate, R1 is —(CH2)17—CH3, R2 is CH3, R3 is H, R4 is —(CH2)2—, and R5 is CH3.

### Claim 32 (depends on 30)

The use according to claim 30, wherein the medicament is a pharmaceutical solid dosage form for oral administration, preferably an enteric dosage form.

### Claim 33 (depends on 32)

The use according to claim 32, wherein the pharmaceutical solid dosage form is selected from the group consisting of tablets, pills, capsules, and granules.

### Claim 34 (depends on 30)

The use according to claim 30, wherein the hematological malignancies are selected from the group consisting of leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome, with the leukemia preferably being selected from the group consisting of acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, and chronic lymphoid leukemia; or with the lymphoma preferably being selected from the group consisting of Hodgkin lymphoma and non-Hodgkin lymphoma.

### Claim 35 (depends on 30)

The use according to claim 30, wherein the medicament is used in combination with at least one other pharmaceutical comprising one or more additional active ingredients.

### Claim 36 (depends on 35)

The use according to claim 35, wherein the one or more additional active ingredients are selected from the group consisting of anti-neoplastic agents.

### Claim 37 (depends on 36)

The use according to claim 36, wherein the anti-neoplastic agents are selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, inhibitors of topoisomerases I and/or II, steroids, inhibitors of tyrosine kinases, proteosome inhibitors, and DNA intercalating agents, with the alkylating agents preferably being selected from the group of nitrogen mustards, nitrosoureas, platinum derivatives, and alkylsulfonates; or with the antimetabolites preferably being selected from the group consisting of methotrexate, purine analogs, and pyrimidine analogs.

### Claim 38 (depends on 36)

The use according to claim 36, wherein the anti-neoplastic agents are selected from the group consisting of chlorambucil, cyclophosphamide, melphalan, mechlorethamine, carmustine, cisplatin, carboplatin, busulfan, treosulfan, methotrexate, fludarabine, clofarabine, pentostatine, cladribine, cytarabine, decitabine, vincristine, vinblastine, mitoxantrone, epirubicin, doxorubicin, daunorubicin, bleomycin, etoposide, teniposide, dexamethasone, imatinib, bortezomib, amsacrine, and thalidomide.

### Claim 39 (depends on 35)

The use according to claim 35, wherein the one or more additional active ingredients are selected from the group of antibodies, wherein said antibodies are directed against one or more epitopes on the cell surface of hematological cells.

### Claim 40 (depends on 30)

Tri-substituted glycerol compound as defined in claim 30 for the treatment of hematological malignancies, wherein the hematological malignancies are preferably selected from the group consisting of leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome.

### Claim 41 (depends on 30)

Method for the treatment of hematological malignancies, comprising:
(a) administering to a patient a medicament or a combination of medicaments as defined in claim 30; and optionally
(b) determining the extent of Fas receptor gene expression in one or more malignant cells of the patient to be treated before administering the medicament or the combination of medicaments.

### Claim 42 (depends on 41)

The method according to claim 41, further comprising:
(c) determining one or more of the following in the one or more tumor cells of the patient to be treated before administering the medicament or the combination of medicaments:
(i) the presence or absence of one or more ras gene mutations;
(ii) the presence or absence of one or more FGFR3 gene mutations; and
(iii) the presence or absence of one or more PTEN gene mutations,
wherein the presence or absence of the one or more FGFR3 gene mutations is preferably determined in the concomitant presence of the t(4;14) chromosomal translocation.

### Claim 43 (depends on 41, 42)

The method according to claim 41 or 42, further comprising:
(d) comparing the results of the measurements obtained in (b) and/or (c) with those obtained in one or more control cells.

### Claim 44 (depends on 30)

In vitro method for determining the susceptibility of one or more malignant cells to a medicament or a combination of medicaments as defined in claim 30, the method comprising:
(a) determining the extent of Fas receptor gene expression in the one or more malignant cells.

### Claim 45 (depends on 44)

The in vitro method according to claim 44, further comprising:
(b) determining one or more of the following in the one or more malignant cells:
(i) the presence or absence of one or more ras gene mutations;
(ii) the presence or absence of one or more FGFR3 gene mutations; and
(iii) the presence or absence of one or more PTEN gene mutations,
wherein the presence or absence of the one or more FGFR3 gene mutations is preferably determined in the concomitant presence of the t(4;14) chromosomal translocation.

### Claim 46 (depends on 44, 45)

The in vitro method according to claim 44 or 45, further comprising:
(c) comparing the results of the measurements obtained in (a) and/or (b) with those obtained in one or more control cells.

### Claim 47 (depends on 30)

Kit-of-parts, comprising a medicament as defined in claim 30.

### Claim 48 (depends on 35, 47)

The kit-of-parts according to claim 47, further comprising a medicament as defined in claim 35.

### Claim 49 (depends on 40)

Kit-of-parts, comprising a tri-substituted glycerol compound as defined in claim 40.
